
Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ:INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities.
The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio Pharmaceuticals from Underperform to Neutral while raising the price target from $8 to $10.